Private Advisor Group LLC trimmed its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 11.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 114,226 shares of the biopharmaceutical company’s stock after selling 14,071 shares during the period. Private Advisor Group LLC’s holdings in Bristol-Myers Squibb were worth $7,226,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. BlackRock Inc. raised its stake in Bristol-Myers Squibb by 5.0% in the fourth quarter. BlackRock Inc. now owns 104,293,294 shares of the biopharmaceutical company’s stock worth $6,391,093,000 after buying an additional 4,945,515 shares in the last quarter. Renaissance Technologies LLC raised its stake in Bristol-Myers Squibb by 31.9% in the fourth quarter. Renaissance Technologies LLC now owns 14,302,900 shares of the biopharmaceutical company’s stock worth $876,482,000 after buying an additional 3,456,300 shares in the last quarter. TIAA CREF Investment Management LLC raised its stake in Bristol-Myers Squibb by 30.8% in the fourth quarter. TIAA CREF Investment Management LLC now owns 10,932,722 shares of the biopharmaceutical company’s stock worth $669,957,000 after buying an additional 2,573,967 shares in the last quarter. Orbis Allan Gray Ltd raised its stake in Bristol-Myers Squibb by 31.1% in the fourth quarter. Orbis Allan Gray Ltd now owns 6,901,670 shares of the biopharmaceutical company’s stock worth $422,935,000 after buying an additional 1,635,666 shares in the last quarter. Finally, Amundi Pioneer Asset Management Inc. raised its stake in Bristol-Myers Squibb by 109.0% in the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 2,797,167 shares of the biopharmaceutical company’s stock worth $171,409,000 after buying an additional 1,458,723 shares in the last quarter. 71.29% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Dinesh C. Paliwal bought 4,770 shares of the company’s stock in a transaction that occurred on Monday, April 30th. The shares were bought at an average price of $52.40 per share, for a total transaction of $249,948.00. Following the completion of the acquisition, the director now owns 8,027 shares of the company’s stock, valued at approximately $420,614.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.12% of the company’s stock.
Shares of BMY stock opened at $52.71 on Monday. Bristol-Myers Squibb Co has a 12-month low of $49.96 and a 12-month high of $70.05. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.39 and a current ratio of 1.52. The company has a market capitalization of $86.16 billion, a P/E ratio of 16.95, a P/E/G ratio of 1.32 and a beta of 0.99.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. The company had revenue of $5.19 billion for the quarter, compared to analysts’ expectations of $5.25 billion. During the same quarter last year, the company posted $0.84 earnings per share. The firm’s quarterly revenue was up 5.4% on a year-over-year basis. equities analysts predict that Bristol-Myers Squibb Co will post 3.41 EPS for the current year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, May 1st. Investors of record on Friday, April 6th were issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 3.04%. The ex-dividend date was Thursday, April 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.
BMY has been the subject of a number of research reports. Morgan Stanley raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $51.56 to $78.00 in a research note on Thursday, February 15th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. Jefferies Group set a $70.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Friday, March 23rd. BMO Capital Markets reissued a “sell” rating and issued a $52.00 price target on shares of Bristol-Myers Squibb in a research note on Monday, January 22nd. Finally, Argus reissued a “buy” rating and issued a $66.43 price target (down from $75.00) on shares of Bristol-Myers Squibb in a research note on Wednesday, March 21st. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the company’s stock. Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $63.68.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.